Histone deacetylases inhibitors: Conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment

Expert Opinion on Investigational Drugs

Volumn 23, Issue 3, 2014, Pages 291-294

  Papavassiliou, Konstantinos A ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anti tumour pharmacophore; Cancer treatment; Conjugation; Histone deacetylase inhibitor; Multi targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS;

EID: 84894069675     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.857401     Document Type: Review

References (21)

1. Thurn KT, Thomas S, Moore A, et al. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011;7:263-83
2. Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: The next step? Cancer Lett 2009;280:211-21
3. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119:2579-89
4. Balasubramanian S, Ramos J, Luo W, et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008;22:1026-34
5. Minami J, Suzuki R, Mazitschek R, et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 2013, doi:10.1038/leu.2013.231
6. Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011;29:255-65
7. Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012;4:505-24
8. Morphy R, Rankovic Z. Designing multiple ligands - medicinal chemistry strategies and challenges. Curr Pharm Des 2009;15:587-600
9. Zhang X, Zhang J, Tong L, et al. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents. Bioorg Med Chem 2013;21:3240-4
10. Fischer J, Wang TT, Kaldre D, et al. Synthetically accessible non-secosteroidal hybrid molecules combining vitamin D receptor agonism and histone deacetylase inhibition. Chem Biol 2012;19:963-71
11. Zhang X, Su M, Chen Y, et al. The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors. Molecules 2013;18:6491-503
12. Lai CJ, Bao R, Tao X, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 2010;70:3647-56
13. Guerrant W, Patil V, Canzoneri JC, et al. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J Med Chem 2012;55:1465-77
14. Guerrant W, Patil V, Canzoneri JC, et al. Dual-Acting histone deacetylasetopoisomerase I inhibitors. Bioorg Med Chem Lett 2013;23:3283-7
15. Griffith D, Morgan M, Marmion CJ. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chem Commun 2009;6735-7
16. Brabec V, Griffith DM, Kisova A, et al. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH(3))(2)malSAHA(-2H))]. Mol Pharm 2012;9:1990-9
17. Yang J, Sun X, Mao W, et al. Conjugate of Pt(IV)-histone deacetylase inhibitor as a prodrug for cancer chemotherapy. Mol Pharm 2012;10:2793-800
18. Chen L, Wilson D, Jayaram HN, et al. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem 2007;50:6685-91
19. Chetan B, Bunha M, Jagrat M, et al. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity. Bioorg Med Chem Lett 2010;20:3906-10
20. Chen JB, Chern TR, Wei TT, et al. Design and synthesis of dual-Action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment. J Med Chem 2013;56:3645-55
21. Passarella D, Comi D, Vanossi A, et al. Histone deacetylase and microtubules as targets for the synthesis of releasable conjugate compounds. Bioorg Med Chem Lett 2009;19:6358-63